Standard pharmacological care for RA includes treatment with methotrexate, TNFα (also known as TNF) inhibitors (e.g. adalimumab, infliximab, etanercept), glucocorticoids (e.g. prednisolone), B- and T-cell inhibitors (e.g. abatacept, rituximab), and interleukin (IL)-1, -6 and -17 blockers (such as anakinra, tocilizumab, secukinumab), all of which cause severe side effects due to their immunosuppressive mode of action (Rein and Mueller, 2017). The gene discussed is TNF; the disease is rheumatoid arthritis.